This structure allows Ipsen to maintain the strong growth momentum it has built up in recent years by providing differentiated and innovative specialty care medicines to address unmet medical needs.

Medical director of Ipsen UK and Ireland, Manjinder Bains, commented: “At this stage of the disease, it is critical to intervene with another treatment that can prolong survival and delay ...

Over the last 30 years in the neurotoxins market, Ipsen has established itself as one of the leading players in neurosciences, successfully driving research, clinical development and growth based on ...

According to Ipsen’s chief medical officer, Sandra Silvestri, the lack of effective PBC treatment can lead to advanced forms of the disease where liver transplantation may be the only option.

“Ipsen delivered solid results and advanced ... (NETs), with study results presented at the 2024 European Society for Medical Oncology (ESMO) Congress and published in the New England Journal ...

CEO David Loew emphasized Ipsen’s sustained growth in 2024, with total sales increasing by 9.9%. He highlighted the strong performance of the ex-Somatuline portfolio, which grew by 12.2% ...

Ipsen is a global biotechnology company headquartered ... Onivyde addresses a high unmet medical need in second-line pancreatic cancer, and it has achieved market-share gains and volume growth ...

PARIS, FRANCE, March 12th, 2025 - Ipsen (Euronext: IPN; ADR: IPSEY), a global specialty care-driven company, announced today the appointment of Olivia Brown as, EVP, Global Head of Neurotoxins ...